Skip to main content

Table 3 Disease and demographic characteristics of patients based on the status of protective antibody levels at 1

From: Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs

  Patients with protective antibody levels at 1.5 years of follow-up
(n= 132)
Patients without protective antibody levels at 1.5 years of follow-up
(n= 170)
P value
Age (years); mean (SD) (range) 51.7 (13) (24-79) 60.1 (11) (30-85) P < 0.001 a
Patient age ≥65 years (%) 16% 37% P < 0.001 b
Gender (female %) 58% 72% P = 0.01 b
Disease duration (years); mean (SD) (range) 13.8 (10) (0-45) 16.7 (11) (0-46) P = 0.039 a
DAS at vaccination; mean (SD) (range) 3.0 (1.3) (0-5.6) 3.5 (1) (0-6.4) P = 0.001 a
HAQ at vaccination; mean (SD) (range) 0.6 (0.5) (0-2) 0.9 (0.7) (0-3) P < 0.001 a
RA (yes, %) 38/62 66/34 P < 0.001 b
Ongoing MTX (yes, %) 44% 61% P < 0.001 b
Ongoing anti-TNF treatment (yes, %) 60% 72% P = 0.029 b
Positive antibody response for 6B and 23F at 4 to 6 weeks of follow-up (yes, %) 37.1% 25% P = 0.027 b
Protective antibody levels for both 6B and 23F serotypes at vaccination (%) 72% 20.6% P < 0.001 b
  1. aMann-Whitney U test. bχ2 test.